Login / Signup

Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies.

Zachary Ryan McCawLu TianDae Hyun KimA Russell LocalioLee-Jen Wei
Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported.
Keyphrases
  • coronavirus disease
  • cardiovascular disease
  • respiratory syndrome coronavirus
  • risk factors
  • combination therapy
  • replacement therapy